Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 10, 2026
- Bionano Genomics reported third-quarter revenue of $8.3 million, up 12% from $7.4 million, and gross margin of 48%, up from 46%. It reiterated full year 2026 revenue guidance of $31 to $33 million.
- 10-Q report · filed Nov 10, 2026
- Bionano Genomics reported revenue of $23.1 million, up 13%, and a $22.2 million net loss for the nine months ended September 30, 2026. It faces substantial doubt about going concern and expects additional capital in the very near term.
The audio replay and transcript follow the call.